nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—ABCG2—Vismodegib—skin cancer	0.0888	0.113	CbGbCtD
Buprenorphine—ABCG2—Vemurafenib—skin cancer	0.0702	0.0893	CbGbCtD
Buprenorphine—CYP1A2—Imiquimod—skin cancer	0.0528	0.0672	CbGbCtD
Buprenorphine—CYP2C8—Vismodegib—skin cancer	0.0473	0.0602	CbGbCtD
Buprenorphine—ABCG2—Dactinomycin—skin cancer	0.0466	0.0593	CbGbCtD
Buprenorphine—CYP2C19—Vismodegib—skin cancer	0.0397	0.0505	CbGbCtD
Buprenorphine—CYP2A6—Fluorouracil—skin cancer	0.0341	0.0433	CbGbCtD
Buprenorphine—CYP2C9—Vismodegib—skin cancer	0.033	0.042	CbGbCtD
Buprenorphine—ABCB1—Vismodegib—skin cancer	0.032	0.0407	CbGbCtD
Buprenorphine—ABCG2—Fluorouracil—skin cancer	0.0315	0.0401	CbGbCtD
Buprenorphine—CYP1A2—Vemurafenib—skin cancer	0.0289	0.0368	CbGbCtD
Buprenorphine—CYP3A4—Imiquimod—skin cancer	0.0277	0.0352	CbGbCtD
Buprenorphine—CYP3A4—Temozolomide—skin cancer	0.0277	0.0352	CbGbCtD
Buprenorphine—ABCG2—Docetaxel—skin cancer	0.0241	0.0306	CbGbCtD
Buprenorphine—CYP2D6—Vemurafenib—skin cancer	0.0238	0.0303	CbGbCtD
Buprenorphine—CYP1A2—Dacarbazine—skin cancer	0.0222	0.0282	CbGbCtD
Buprenorphine—CYP3A4—Vismodegib—skin cancer	0.0192	0.0244	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0178	0.0226	CbGbCtD
Buprenorphine—CYP3A7—Docetaxel—skin cancer	0.0178	0.0226	CbGbCtD
Buprenorphine—ABCB1—Dactinomycin—skin cancer	0.0168	0.0214	CbGbCtD
Buprenorphine—CYP2C8—Fluorouracil—skin cancer	0.0168	0.0214	CbGbCtD
Buprenorphine—CYP3A4—Vemurafenib—skin cancer	0.0152	0.0193	CbGbCtD
Buprenorphine—CYP3A5—Docetaxel—skin cancer	0.0133	0.017	CbGbCtD
Buprenorphine—CYP1A2—Fluorouracil—skin cancer	0.013	0.0165	CbGbCtD
Buprenorphine—CYP2C9—Fluorouracil—skin cancer	0.0117	0.0149	CbGbCtD
Buprenorphine—ABCB1—Docetaxel—skin cancer	0.00868	0.011	CbGbCtD
Buprenorphine—CYP3A4—Docetaxel—skin cancer	0.0052	0.00662	CbGbCtD
Buprenorphine—Abdominal pain—Imiquimod—skin cancer	0.00027	0.00128	CcSEcCtD
Buprenorphine—Body temperature increased—Imiquimod—skin cancer	0.00027	0.00128	CcSEcCtD
Buprenorphine—Eye disorder—Temozolomide—skin cancer	0.000269	0.00128	CcSEcCtD
Buprenorphine—Tinnitus—Temozolomide—skin cancer	0.000268	0.00127	CcSEcCtD
Buprenorphine—Malaise—Bleomycin—skin cancer	0.000268	0.00127	CcSEcCtD
Buprenorphine—Flushing—Temozolomide—skin cancer	0.000267	0.00127	CcSEcCtD
Buprenorphine—Cardiac disorder—Temozolomide—skin cancer	0.000267	0.00127	CcSEcCtD
Buprenorphine—Rhinitis—Fluorouracil—skin cancer	0.000266	0.00126	CcSEcCtD
Buprenorphine—Dizziness—Vemurafenib—skin cancer	0.000265	0.00126	CcSEcCtD
Buprenorphine—Hypoaesthesia—Fluorouracil—skin cancer	0.000264	0.00125	CcSEcCtD
Buprenorphine—Pharyngitis—Fluorouracil—skin cancer	0.000263	0.00125	CcSEcCtD
Buprenorphine—Angiopathy—Temozolomide—skin cancer	0.000261	0.00124	CcSEcCtD
Buprenorphine—Immune system disorder—Temozolomide—skin cancer	0.00026	0.00124	CcSEcCtD
Buprenorphine—Mediastinal disorder—Temozolomide—skin cancer	0.000259	0.00123	CcSEcCtD
Buprenorphine—Cough—Bleomycin—skin cancer	0.000259	0.00123	CcSEcCtD
Buprenorphine—Chills—Temozolomide—skin cancer	0.000258	0.00123	CcSEcCtD
Buprenorphine—Dehydration—Docetaxel—skin cancer	0.000257	0.00122	CcSEcCtD
Buprenorphine—Ill-defined disorder—Dactinomycin—skin cancer	0.000257	0.00122	CcSEcCtD
Buprenorphine—Vomiting—Vemurafenib—skin cancer	0.000254	0.00121	CcSEcCtD
Buprenorphine—Dry skin—Docetaxel—skin cancer	0.000254	0.0012	CcSEcCtD
Buprenorphine—Myalgia—Bleomycin—skin cancer	0.000253	0.0012	CcSEcCtD
Buprenorphine—Chest pain—Bleomycin—skin cancer	0.000253	0.0012	CcSEcCtD
Buprenorphine—Orthostatic hypotension—Docetaxel—skin cancer	0.000253	0.0012	CcSEcCtD
Buprenorphine—Abdominal pain upper—Docetaxel—skin cancer	0.000253	0.0012	CcSEcCtD
Buprenorphine—Rash—Vemurafenib—skin cancer	0.000252	0.0012	CcSEcCtD
Buprenorphine—Mental disorder—Temozolomide—skin cancer	0.000252	0.0012	CcSEcCtD
Buprenorphine—Dermatitis—Vemurafenib—skin cancer	0.000252	0.0012	CcSEcCtD
Buprenorphine—Hypersensitivity—Imiquimod—skin cancer	0.000251	0.00119	CcSEcCtD
Buprenorphine—Headache—Vemurafenib—skin cancer	0.000251	0.00119	CcSEcCtD
Buprenorphine—Malnutrition—Temozolomide—skin cancer	0.000251	0.00119	CcSEcCtD
Buprenorphine—Erythema—Temozolomide—skin cancer	0.000251	0.00119	CcSEcCtD
Buprenorphine—Breast disorder—Docetaxel—skin cancer	0.00025	0.00119	CcSEcCtD
Buprenorphine—Discomfort—Bleomycin—skin cancer	0.00025	0.00119	CcSEcCtD
Buprenorphine—Malaise—Dactinomycin—skin cancer	0.00025	0.00119	CcSEcCtD
Buprenorphine—Cramp muscle—Docetaxel—skin cancer	0.000249	0.00118	CcSEcCtD
Buprenorphine—Nasopharyngitis—Docetaxel—skin cancer	0.000247	0.00118	CcSEcCtD
Buprenorphine—Dysgeusia—Temozolomide—skin cancer	0.000245	0.00117	CcSEcCtD
Buprenorphine—Asthenia—Imiquimod—skin cancer	0.000245	0.00116	CcSEcCtD
Buprenorphine—Confusional state—Bleomycin—skin cancer	0.000245	0.00116	CcSEcCtD
Buprenorphine—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000244	0.00116	CcSEcCtD
Buprenorphine—Anaphylactic shock—Bleomycin—skin cancer	0.000242	0.00115	CcSEcCtD
Buprenorphine—Oedema—Bleomycin—skin cancer	0.000242	0.00115	CcSEcCtD
Buprenorphine—Back pain—Temozolomide—skin cancer	0.000242	0.00115	CcSEcCtD
Buprenorphine—Pruritus—Imiquimod—skin cancer	0.000241	0.00115	CcSEcCtD
Buprenorphine—Infection—Bleomycin—skin cancer	0.000241	0.00114	CcSEcCtD
Buprenorphine—Dysphagia—Docetaxel—skin cancer	0.000239	0.00114	CcSEcCtD
Buprenorphine—Nausea—Vemurafenib—skin cancer	0.000238	0.00113	CcSEcCtD
Buprenorphine—Vision blurred—Temozolomide—skin cancer	0.000236	0.00112	CcSEcCtD
Buprenorphine—Myalgia—Dactinomycin—skin cancer	0.000236	0.00112	CcSEcCtD
Buprenorphine—Bronchospasm—Docetaxel—skin cancer	0.000235	0.00112	CcSEcCtD
Buprenorphine—Tremor—Temozolomide—skin cancer	0.000235	0.00112	CcSEcCtD
Buprenorphine—Diarrhoea—Imiquimod—skin cancer	0.000234	0.00111	CcSEcCtD
Buprenorphine—Discomfort—Dactinomycin—skin cancer	0.000233	0.00111	CcSEcCtD
Buprenorphine—Angina pectoris—Docetaxel—skin cancer	0.000233	0.00111	CcSEcCtD
Buprenorphine—Ill-defined disorder—Temozolomide—skin cancer	0.000233	0.0011	CcSEcCtD
Buprenorphine—Anorexia—Bleomycin—skin cancer	0.000231	0.0011	CcSEcCtD
Buprenorphine—Erythema—Fluorouracil—skin cancer	0.000231	0.0011	CcSEcCtD
Buprenorphine—Agitation—Temozolomide—skin cancer	0.00023	0.00109	CcSEcCtD
Buprenorphine—Angioedema—Temozolomide—skin cancer	0.000229	0.00109	CcSEcCtD
Buprenorphine—Hypotension—Bleomycin—skin cancer	0.000227	0.00108	CcSEcCtD
Buprenorphine—Oedema—Dactinomycin—skin cancer	0.000226	0.00107	CcSEcCtD
Buprenorphine—Malaise—Temozolomide—skin cancer	0.000226	0.00107	CcSEcCtD
Buprenorphine—Dizziness—Imiquimod—skin cancer	0.000226	0.00107	CcSEcCtD
Buprenorphine—Vertigo—Temozolomide—skin cancer	0.000225	0.00107	CcSEcCtD
Buprenorphine—Infection—Dactinomycin—skin cancer	0.000225	0.00107	CcSEcCtD
Buprenorphine—Palpitations—Temozolomide—skin cancer	0.000221	0.00105	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000221	0.00105	CcSEcCtD
Buprenorphine—Cough—Temozolomide—skin cancer	0.000219	0.00104	CcSEcCtD
Buprenorphine—Paraesthesia—Bleomycin—skin cancer	0.000218	0.00103	CcSEcCtD
Buprenorphine—Vision blurred—Fluorouracil—skin cancer	0.000218	0.00103	CcSEcCtD
Buprenorphine—Convulsion—Temozolomide—skin cancer	0.000217	0.00103	CcSEcCtD
Buprenorphine—Vomiting—Imiquimod—skin cancer	0.000217	0.00103	CcSEcCtD
Buprenorphine—Weight decreased—Docetaxel—skin cancer	0.000216	0.00103	CcSEcCtD
Buprenorphine—Hypertension—Temozolomide—skin cancer	0.000216	0.00103	CcSEcCtD
Buprenorphine—Dyspnoea—Bleomycin—skin cancer	0.000216	0.00103	CcSEcCtD
Buprenorphine—Anorexia—Dactinomycin—skin cancer	0.000216	0.00102	CcSEcCtD
Buprenorphine—Rash—Imiquimod—skin cancer	0.000215	0.00102	CcSEcCtD
Buprenorphine—Dermatitis—Imiquimod—skin cancer	0.000215	0.00102	CcSEcCtD
Buprenorphine—Headache—Imiquimod—skin cancer	0.000214	0.00102	CcSEcCtD
Buprenorphine—Arthralgia—Temozolomide—skin cancer	0.000213	0.00101	CcSEcCtD
Buprenorphine—Myalgia—Temozolomide—skin cancer	0.000213	0.00101	CcSEcCtD
Buprenorphine—Infestation NOS—Docetaxel—skin cancer	0.000213	0.00101	CcSEcCtD
Buprenorphine—Infestation—Docetaxel—skin cancer	0.000213	0.00101	CcSEcCtD
Buprenorphine—Anxiety—Temozolomide—skin cancer	0.000213	0.00101	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000212	0.00101	CcSEcCtD
Buprenorphine—Discomfort—Temozolomide—skin cancer	0.000211	0.001	CcSEcCtD
Buprenorphine—Decreased appetite—Bleomycin—skin cancer	0.000211	0.001	CcSEcCtD
Buprenorphine—Dry mouth—Temozolomide—skin cancer	0.000209	0.000991	CcSEcCtD
Buprenorphine—Pain—Bleomycin—skin cancer	0.000207	0.000985	CcSEcCtD
Buprenorphine—Conjunctivitis—Docetaxel—skin cancer	0.000207	0.000985	CcSEcCtD
Buprenorphine—Confusional state—Temozolomide—skin cancer	0.000206	0.000979	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000206	0.000979	CcSEcCtD
Buprenorphine—Anaphylactic shock—Temozolomide—skin cancer	0.000205	0.000971	CcSEcCtD
Buprenorphine—Oedema—Temozolomide—skin cancer	0.000205	0.000971	CcSEcCtD
Buprenorphine—Infection—Temozolomide—skin cancer	0.000203	0.000965	CcSEcCtD
Buprenorphine—Nausea—Imiquimod—skin cancer	0.000203	0.000963	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Docetaxel—skin cancer	0.000202	0.000958	CcSEcCtD
Buprenorphine—Nervous system disorder—Temozolomide—skin cancer	0.000201	0.000953	CcSEcCtD
Buprenorphine—Convulsion—Fluorouracil—skin cancer	0.0002	0.00095	CcSEcCtD
Buprenorphine—Feeling abnormal—Bleomycin—skin cancer	0.0002	0.000949	CcSEcCtD
Buprenorphine—Skin disorder—Temozolomide—skin cancer	0.000199	0.000944	CcSEcCtD
Buprenorphine—Hyperhidrosis—Temozolomide—skin cancer	0.000198	0.000939	CcSEcCtD
Buprenorphine—Chest pain—Fluorouracil—skin cancer	0.000197	0.000934	CcSEcCtD
Buprenorphine—Myalgia—Fluorouracil—skin cancer	0.000197	0.000934	CcSEcCtD
Buprenorphine—Decreased appetite—Dactinomycin—skin cancer	0.000197	0.000934	CcSEcCtD
Buprenorphine—Fatigue—Dactinomycin—skin cancer	0.000195	0.000926	CcSEcCtD
Buprenorphine—Anorexia—Temozolomide—skin cancer	0.000195	0.000926	CcSEcCtD
Buprenorphine—Discomfort—Fluorouracil—skin cancer	0.000194	0.000922	CcSEcCtD
Buprenorphine—Pain—Dactinomycin—skin cancer	0.000193	0.000918	CcSEcCtD
Buprenorphine—Urticaria—Bleomycin—skin cancer	0.000193	0.000915	CcSEcCtD
Buprenorphine—Rhinitis—Docetaxel—skin cancer	0.000192	0.000912	CcSEcCtD
Buprenorphine—Body temperature increased—Bleomycin—skin cancer	0.000192	0.00091	CcSEcCtD
Buprenorphine—Hypoaesthesia—Docetaxel—skin cancer	0.000191	0.000905	CcSEcCtD
Buprenorphine—Confusional state—Fluorouracil—skin cancer	0.00019	0.000902	CcSEcCtD
Buprenorphine—Pharyngitis—Docetaxel—skin cancer	0.00019	0.000902	CcSEcCtD
Buprenorphine—Urinary tract disorder—Docetaxel—skin cancer	0.000189	0.000898	CcSEcCtD
Buprenorphine—Oedema peripheral—Docetaxel—skin cancer	0.000189	0.000896	CcSEcCtD
Buprenorphine—Oedema—Fluorouracil—skin cancer	0.000188	0.000895	CcSEcCtD
Buprenorphine—Anaphylactic shock—Fluorouracil—skin cancer	0.000188	0.000895	CcSEcCtD
Buprenorphine—Connective tissue disorder—Docetaxel—skin cancer	0.000188	0.000894	CcSEcCtD
Buprenorphine—Urethral disorder—Docetaxel—skin cancer	0.000188	0.000891	CcSEcCtD
Buprenorphine—Infection—Fluorouracil—skin cancer	0.000187	0.000889	CcSEcCtD
Buprenorphine—Feeling abnormal—Dactinomycin—skin cancer	0.000186	0.000885	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000186	0.000885	CcSEcCtD
Buprenorphine—Insomnia—Temozolomide—skin cancer	0.000185	0.000879	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Dactinomycin—skin cancer	0.000185	0.000878	CcSEcCtD
Buprenorphine—Nervous system disorder—Fluorouracil—skin cancer	0.000185	0.000878	CcSEcCtD
Buprenorphine—Visual impairment—Docetaxel—skin cancer	0.000185	0.000876	CcSEcCtD
Buprenorphine—Tachycardia—Fluorouracil—skin cancer	0.000184	0.000874	CcSEcCtD
Buprenorphine—Paraesthesia—Temozolomide—skin cancer	0.000184	0.000872	CcSEcCtD
Buprenorphine—Dyspnoea—Temozolomide—skin cancer	0.000182	0.000866	CcSEcCtD
Buprenorphine—Somnolence—Temozolomide—skin cancer	0.000182	0.000864	CcSEcCtD
Buprenorphine—Dyspepsia—Temozolomide—skin cancer	0.00018	0.000855	CcSEcCtD
Buprenorphine—Anorexia—Fluorouracil—skin cancer	0.00018	0.000853	CcSEcCtD
Buprenorphine—Eye disorder—Docetaxel—skin cancer	0.000179	0.00085	CcSEcCtD
Buprenorphine—Body temperature increased—Dactinomycin—skin cancer	0.000179	0.000849	CcSEcCtD
Buprenorphine—Abdominal pain—Dactinomycin—skin cancer	0.000179	0.000849	CcSEcCtD
Buprenorphine—Hypersensitivity—Bleomycin—skin cancer	0.000179	0.000848	CcSEcCtD
Buprenorphine—Decreased appetite—Temozolomide—skin cancer	0.000178	0.000844	CcSEcCtD
Buprenorphine—Cardiac disorder—Docetaxel—skin cancer	0.000178	0.000844	CcSEcCtD
Buprenorphine—Flushing—Docetaxel—skin cancer	0.000178	0.000844	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000177	0.000839	CcSEcCtD
Buprenorphine—Fatigue—Temozolomide—skin cancer	0.000176	0.000838	CcSEcCtD
Buprenorphine—Hypotension—Fluorouracil—skin cancer	0.000176	0.000836	CcSEcCtD
Buprenorphine—Pain—Temozolomide—skin cancer	0.000175	0.000831	CcSEcCtD
Buprenorphine—Constipation—Temozolomide—skin cancer	0.000175	0.000831	CcSEcCtD
Buprenorphine—Asthenia—Bleomycin—skin cancer	0.000174	0.000826	CcSEcCtD
Buprenorphine—Angiopathy—Docetaxel—skin cancer	0.000174	0.000825	CcSEcCtD
Buprenorphine—Immune system disorder—Docetaxel—skin cancer	0.000173	0.000821	CcSEcCtD
Buprenorphine—Mediastinal disorder—Docetaxel—skin cancer	0.000173	0.000819	CcSEcCtD
Buprenorphine—Chills—Docetaxel—skin cancer	0.000172	0.000816	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000172	0.000815	CcSEcCtD
Buprenorphine—Pruritus—Bleomycin—skin cancer	0.000172	0.000815	CcSEcCtD
Buprenorphine—Insomnia—Fluorouracil—skin cancer	0.00017	0.00081	CcSEcCtD
Buprenorphine—Paraesthesia—Fluorouracil—skin cancer	0.000169	0.000804	CcSEcCtD
Buprenorphine—Feeling abnormal—Temozolomide—skin cancer	0.000169	0.0008	CcSEcCtD
Buprenorphine—Dyspnoea—Fluorouracil—skin cancer	0.000168	0.000798	CcSEcCtD
Buprenorphine—Mental disorder—Docetaxel—skin cancer	0.000168	0.000797	CcSEcCtD
Buprenorphine—Somnolence—Fluorouracil—skin cancer	0.000168	0.000796	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Temozolomide—skin cancer	0.000167	0.000794	CcSEcCtD
Buprenorphine—Erythema—Docetaxel—skin cancer	0.000167	0.000792	CcSEcCtD
Buprenorphine—Malnutrition—Docetaxel—skin cancer	0.000167	0.000792	CcSEcCtD
Buprenorphine—Hypersensitivity—Dactinomycin—skin cancer	0.000167	0.000791	CcSEcCtD
Buprenorphine—Dyspepsia—Fluorouracil—skin cancer	0.000166	0.000788	CcSEcCtD
Buprenorphine—Decreased appetite—Fluorouracil—skin cancer	0.000164	0.000778	CcSEcCtD
Buprenorphine—Dysgeusia—Docetaxel—skin cancer	0.000163	0.000775	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000163	0.000773	CcSEcCtD
Buprenorphine—Urticaria—Temozolomide—skin cancer	0.000163	0.000772	CcSEcCtD
Buprenorphine—Asthenia—Dactinomycin—skin cancer	0.000162	0.000771	CcSEcCtD
Buprenorphine—Abdominal pain—Temozolomide—skin cancer	0.000162	0.000768	CcSEcCtD
Buprenorphine—Body temperature increased—Temozolomide—skin cancer	0.000162	0.000768	CcSEcCtD
Buprenorphine—Back pain—Docetaxel—skin cancer	0.000161	0.000766	CcSEcCtD
Buprenorphine—Pain—Fluorouracil—skin cancer	0.000161	0.000765	CcSEcCtD
Buprenorphine—Muscle spasms—Docetaxel—skin cancer	0.00016	0.000761	CcSEcCtD
Buprenorphine—Feeling abnormal—Fluorouracil—skin cancer	0.000155	0.000738	CcSEcCtD
Buprenorphine—Diarrhoea—Dactinomycin—skin cancer	0.000155	0.000735	CcSEcCtD
Buprenorphine—Vomiting—Bleomycin—skin cancer	0.000154	0.000732	CcSEcCtD
Buprenorphine—Rash—Bleomycin—skin cancer	0.000153	0.000726	CcSEcCtD
Buprenorphine—Dermatitis—Bleomycin—skin cancer	0.000153	0.000725	CcSEcCtD
Buprenorphine—Hypersensitivity—Temozolomide—skin cancer	0.000151	0.000716	CcSEcCtD
Buprenorphine—Urticaria—Fluorouracil—skin cancer	0.00015	0.000711	CcSEcCtD
Buprenorphine—Syncope—Docetaxel—skin cancer	0.000149	0.00071	CcSEcCtD
Buprenorphine—Body temperature increased—Fluorouracil—skin cancer	0.000149	0.000708	CcSEcCtD
Buprenorphine—Palpitations—Docetaxel—skin cancer	0.000147	0.000699	CcSEcCtD
Buprenorphine—Asthenia—Temozolomide—skin cancer	0.000147	0.000697	CcSEcCtD
Buprenorphine—Loss of consciousness—Docetaxel—skin cancer	0.000146	0.000696	CcSEcCtD
Buprenorphine—Cough—Docetaxel—skin cancer	0.000145	0.000691	CcSEcCtD
Buprenorphine—Pruritus—Temozolomide—skin cancer	0.000145	0.000687	CcSEcCtD
Buprenorphine—Convulsion—Docetaxel—skin cancer	0.000144	0.000686	CcSEcCtD
Buprenorphine—Nausea—Bleomycin—skin cancer	0.000144	0.000684	CcSEcCtD
Buprenorphine—Hypertension—Docetaxel—skin cancer	0.000144	0.000683	CcSEcCtD
Buprenorphine—Vomiting—Dactinomycin—skin cancer	0.000144	0.000683	CcSEcCtD
Buprenorphine—Rash—Dactinomycin—skin cancer	0.000143	0.000677	CcSEcCtD
Buprenorphine—Arthralgia—Docetaxel—skin cancer	0.000142	0.000674	CcSEcCtD
Buprenorphine—Myalgia—Docetaxel—skin cancer	0.000142	0.000674	CcSEcCtD
Buprenorphine—Chest pain—Docetaxel—skin cancer	0.000142	0.000674	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000141	0.000669	CcSEcCtD
Buprenorphine—Diarrhoea—Temozolomide—skin cancer	0.00014	0.000665	CcSEcCtD
Buprenorphine—Hypersensitivity—Fluorouracil—skin cancer	0.000139	0.000659	CcSEcCtD
Buprenorphine—Dry mouth—Docetaxel—skin cancer	0.000139	0.000659	CcSEcCtD
Buprenorphine—Confusional state—Docetaxel—skin cancer	0.000137	0.000651	CcSEcCtD
Buprenorphine—Oedema—Docetaxel—skin cancer	0.000136	0.000646	CcSEcCtD
Buprenorphine—Anaphylactic shock—Docetaxel—skin cancer	0.000136	0.000646	CcSEcCtD
Buprenorphine—Dizziness—Temozolomide—skin cancer	0.000135	0.000642	CcSEcCtD
Buprenorphine—Infection—Docetaxel—skin cancer	0.000135	0.000642	CcSEcCtD
Buprenorphine—Nausea—Dactinomycin—skin cancer	0.000134	0.000638	CcSEcCtD
Buprenorphine—Shock—Docetaxel—skin cancer	0.000134	0.000636	CcSEcCtD
Buprenorphine—Nervous system disorder—Docetaxel—skin cancer	0.000133	0.000634	CcSEcCtD
Buprenorphine—Pruritus—Fluorouracil—skin cancer	0.000133	0.000633	CcSEcCtD
Buprenorphine—Tachycardia—Docetaxel—skin cancer	0.000133	0.00063	CcSEcCtD
Buprenorphine—Skin disorder—Docetaxel—skin cancer	0.000132	0.000627	CcSEcCtD
Buprenorphine—Vomiting—Temozolomide—skin cancer	0.00013	0.000618	CcSEcCtD
Buprenorphine—Anorexia—Docetaxel—skin cancer	0.00013	0.000616	CcSEcCtD
Buprenorphine—Rash—Temozolomide—skin cancer	0.000129	0.000612	CcSEcCtD
Buprenorphine—Diarrhoea—Fluorouracil—skin cancer	0.000129	0.000612	CcSEcCtD
Buprenorphine—Dermatitis—Temozolomide—skin cancer	0.000129	0.000612	CcSEcCtD
Buprenorphine—Headache—Temozolomide—skin cancer	0.000128	0.000609	CcSEcCtD
Buprenorphine—Hypotension—Docetaxel—skin cancer	0.000127	0.000604	CcSEcCtD
Buprenorphine—Dizziness—Fluorouracil—skin cancer	0.000125	0.000592	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000124	0.000589	CcSEcCtD
Buprenorphine—Insomnia—Docetaxel—skin cancer	0.000123	0.000584	CcSEcCtD
Buprenorphine—Paraesthesia—Docetaxel—skin cancer	0.000122	0.00058	CcSEcCtD
Buprenorphine—Nausea—Temozolomide—skin cancer	0.000122	0.000577	CcSEcCtD
Buprenorphine—Dyspnoea—Docetaxel—skin cancer	0.000121	0.000576	CcSEcCtD
Buprenorphine—Somnolence—Docetaxel—skin cancer	0.000121	0.000574	CcSEcCtD
Buprenorphine—Vomiting—Fluorouracil—skin cancer	0.00012	0.000569	CcSEcCtD
Buprenorphine—Dyspepsia—Docetaxel—skin cancer	0.00012	0.000569	CcSEcCtD
Buprenorphine—Rash—Fluorouracil—skin cancer	0.000119	0.000564	CcSEcCtD
Buprenorphine—Dermatitis—Fluorouracil—skin cancer	0.000119	0.000564	CcSEcCtD
Buprenorphine—Decreased appetite—Docetaxel—skin cancer	0.000118	0.000562	CcSEcCtD
Buprenorphine—Headache—Fluorouracil—skin cancer	0.000118	0.000561	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000117	0.000558	CcSEcCtD
Buprenorphine—Fatigue—Docetaxel—skin cancer	0.000117	0.000557	CcSEcCtD
Buprenorphine—Pain—Docetaxel—skin cancer	0.000116	0.000552	CcSEcCtD
Buprenorphine—Constipation—Docetaxel—skin cancer	0.000116	0.000552	CcSEcCtD
Buprenorphine—Feeling abnormal—Docetaxel—skin cancer	0.000112	0.000532	CcSEcCtD
Buprenorphine—Nausea—Fluorouracil—skin cancer	0.000112	0.000532	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Docetaxel—skin cancer	0.000111	0.000528	CcSEcCtD
Buprenorphine—Abdominal pain—Docetaxel—skin cancer	0.000108	0.000511	CcSEcCtD
Buprenorphine—Body temperature increased—Docetaxel—skin cancer	0.000108	0.000511	CcSEcCtD
Buprenorphine—Hypersensitivity—Docetaxel—skin cancer	0.0001	0.000476	CcSEcCtD
Buprenorphine—Asthenia—Docetaxel—skin cancer	9.76e-05	0.000463	CcSEcCtD
Buprenorphine—Pruritus—Docetaxel—skin cancer	9.62e-05	0.000457	CcSEcCtD
Buprenorphine—Diarrhoea—Docetaxel—skin cancer	9.31e-05	0.000442	CcSEcCtD
Buprenorphine—Dizziness—Docetaxel—skin cancer	9e-05	0.000427	CcSEcCtD
Buprenorphine—Vomiting—Docetaxel—skin cancer	8.65e-05	0.000411	CcSEcCtD
Buprenorphine—Rash—Docetaxel—skin cancer	8.58e-05	0.000407	CcSEcCtD
Buprenorphine—Dermatitis—Docetaxel—skin cancer	8.57e-05	0.000407	CcSEcCtD
Buprenorphine—Headache—Docetaxel—skin cancer	8.52e-05	0.000405	CcSEcCtD
Buprenorphine—Nausea—Docetaxel—skin cancer	8.08e-05	0.000384	CcSEcCtD
Buprenorphine—OPRD1—GPCR ligand binding—PTCH2—skin cancer	2.47e-05	0.00744	CbGpPWpGaD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	2.4e-05	0.00723	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—MC1R—skin cancer	2.36e-05	0.00712	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	2.34e-05	0.00706	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—PTCH2—skin cancer	2.16e-05	0.00652	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—MC1R—skin cancer	2.15e-05	0.00646	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	2.06e-05	0.00619	CbGpPWpGaD
Buprenorphine—ABCG2—HIF-1-alpha transcription factor network—TERT—skin cancer	2.03e-05	0.00612	CbGpPWpGaD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	2.03e-05	0.00611	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—PTCH2—skin cancer	1.83e-05	0.00551	CbGpPWpGaD
Buprenorphine—OPRD1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	1.8e-05	0.00542	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—MC1R—skin cancer	1.78e-05	0.00538	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PTCH2—skin cancer	1.75e-05	0.00528	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	1.74e-05	0.00523	CbGpPWpGaD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	1.58e-05	0.00475	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—MC1R—skin cancer	1.56e-05	0.00471	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—PTGER4—skin cancer	1.55e-05	0.00468	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	1.54e-05	0.00464	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—RHOU—skin cancer	1.53e-05	0.00462	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—SHH—skin cancer	1.53e-05	0.00461	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—SMO—skin cancer	1.45e-05	0.00437	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—PTCH1—skin cancer	1.45e-05	0.00437	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.43e-05	0.00431	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—PTGER4—skin cancer	1.41e-05	0.00425	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	1.35e-05	0.00407	CbGpPWpGaD
Buprenorphine—ABCG2—Fluoropyrimidine Activity—TP53—skin cancer	1.35e-05	0.00406	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RHOU—skin cancer	1.34e-05	0.00405	CbGpPWpGaD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	1.33e-05	0.00402	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—GLI2—skin cancer	1.33e-05	0.004	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—MC1R—skin cancer	1.32e-05	0.00398	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—SHH—skin cancer	1.27e-05	0.00383	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—MC1R—skin cancer	1.27e-05	0.00382	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PTCH2—skin cancer	1.27e-05	0.00382	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—GLI1—skin cancer	1.25e-05	0.00376	CbGpPWpGaD
Buprenorphine—CYP2A6—Fluoropyrimidine Activity—TP53—skin cancer	1.22e-05	0.00368	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—SMO—skin cancer	1.21e-05	0.00363	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—PTCH1—skin cancer	1.21e-05	0.00363	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—SUFU—skin cancer	1.18e-05	0.00357	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—PTGER4—skin cancer	1.17e-05	0.00354	CbGpPWpGaD
Buprenorphine—OPRL1—Circadian rythm related genes—TP53—skin cancer	1.16e-05	0.00348	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	1.14e-05	0.00344	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RHOU—skin cancer	1.14e-05	0.00342	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—SHH—skin cancer	1.12e-05	0.00336	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PTCH2—skin cancer	1.11e-05	0.00335	CbGpPWpGaD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	1.1e-05	0.00331	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.1e-05	0.0033	CbGpPWpGaD
Buprenorphine—OPRL1—Circadian rythm related genes—IL6—skin cancer	1.06e-05	0.00319	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—SMO—skin cancer	1.06e-05	0.00318	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—PTCH1—skin cancer	1.06e-05	0.00318	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—PTGER4—skin cancer	1.03e-05	0.0031	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—MC1R—skin cancer	1.01e-05	0.00304	CbGpPWpGaD
Buprenorphine—CYP2C8—Arachidonic acid metabolism—PTGS2—skin cancer	1.01e-05	0.00303	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—SHH—skin cancer	9.42e-06	0.00284	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PTCH2—skin cancer	9.39e-06	0.00283	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—MC1R—skin cancer	9.16e-06	0.00276	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—SHH—skin cancer	9.03e-06	0.00272	CbGpPWpGaD
Buprenorphine—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	8.99e-06	0.00271	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—RASA1—skin cancer	8.97e-06	0.0027	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—SMO—skin cancer	8.93e-06	0.00269	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—PTCH1—skin cancer	8.93e-06	0.00269	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—MC1R—skin cancer	8.84e-06	0.00266	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—PTGER4—skin cancer	8.7e-06	0.00262	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	8.62e-06	0.0026	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PTCH1—skin cancer	8.56e-06	0.00258	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—SMO—skin cancer	8.56e-06	0.00258	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PTGER4—skin cancer	8.33e-06	0.00251	CbGpPWpGaD
Buprenorphine—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	8.19e-06	0.00247	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	8.17e-06	0.00246	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PLIN2—skin cancer	8.07e-06	0.00243	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—MC1R—skin cancer	8.03e-06	0.00242	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	7.54e-06	0.00227	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	7.48e-06	0.00225	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PTCH2—skin cancer	7.48e-06	0.00225	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—MC1R—skin cancer	7.47e-06	0.00225	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—FOXO4—skin cancer	7.36e-06	0.00222	CbGpPWpGaD
Buprenorphine—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	7e-06	0.00211	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—MC1R—skin cancer	6.79e-06	0.00204	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	6.73e-06	0.00203	CbGpPWpGaD
Buprenorphine—OPRM1—TCR Signaling Pathway—HRAS—skin cancer	6.65e-06	0.002	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—PTGER4—skin cancer	6.63e-06	0.002	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTCH2—skin cancer	6.56e-06	0.00198	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—SHH—skin cancer	6.53e-06	0.00197	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—CSPG4—skin cancer	6.5e-06	0.00196	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PLIN2—skin cancer	6.38e-06	0.00192	CbGpPWpGaD
Buprenorphine—OPRM1—TCR Signaling Pathway—IL6—skin cancer	6.36e-06	0.00192	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PTCH1—skin cancer	6.19e-06	0.00186	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—SMO—skin cancer	6.19e-06	0.00186	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	6.14e-06	0.00185	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PTGER4—skin cancer	6.02e-06	0.00181	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	5.92e-06	0.00178	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	5.82e-06	0.00175	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—PTGER4—skin cancer	5.82e-06	0.00175	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—SHH—skin cancer	5.72e-06	0.00172	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—GLI2—skin cancer	5.67e-06	0.00171	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTCH2—skin cancer	5.55e-06	0.00167	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—SMO—skin cancer	5.42e-06	0.00163	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PTCH1—skin cancer	5.42e-06	0.00163	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PLIN2—skin cancer	5.41e-06	0.00163	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MC1R—skin cancer	5.41e-06	0.00163	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PLIN2—skin cancer	5.36e-06	0.00162	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—GLI1—skin cancer	5.33e-06	0.00161	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PTGER4—skin cancer	5.28e-06	0.00159	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	5.24e-06	0.00158	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—CSPG4—skin cancer	5.14e-06	0.00155	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SUFU—skin cancer	5.05e-06	0.00152	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	5.01e-06	0.00151	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—GLI2—skin cancer	4.97e-06	0.0015	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TERT—skin cancer	4.92e-06	0.00148	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PLIN2—skin cancer	4.92e-06	0.00148	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—PTGER4—skin cancer	4.91e-06	0.00148	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—SHH—skin cancer	4.84e-06	0.00146	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MC1R—skin cancer	4.74e-06	0.00143	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—GLI1—skin cancer	4.68e-06	0.00141	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—SMO—skin cancer	4.58e-06	0.00138	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PTCH1—skin cancer	4.58e-06	0.00138	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PTGER4—skin cancer	4.46e-06	0.00134	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SUFU—skin cancer	4.43e-06	0.00134	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—ENO2—skin cancer	4.42e-06	0.00133	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CSPG4—skin cancer	4.36e-06	0.00131	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CSPG4—skin cancer	4.32e-06	0.0013	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	4.26e-06	0.00128	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—GLI2—skin cancer	4.2e-06	0.00127	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	4.2e-06	0.00127	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—NRAS—skin cancer	4.14e-06	0.00125	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MC1R—skin cancer	4.01e-06	0.00121	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CSPG4—skin cancer	3.96e-06	0.00119	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—GLI1—skin cancer	3.95e-06	0.00119	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—BRAF—skin cancer	3.89e-06	0.00117	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PLIN2—skin cancer	3.88e-06	0.00117	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SHH—skin cancer	3.86e-06	0.00116	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—RASA1—skin cancer	3.83e-06	0.00115	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SUFU—skin cancer	3.75e-06	0.00113	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SMO—skin cancer	3.65e-06	0.0011	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PTCH1—skin cancer	3.65e-06	0.0011	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—KRAS—skin cancer	3.57e-06	0.00107	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PTGER4—skin cancer	3.56e-06	0.00107	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ENO2—skin cancer	3.49e-06	0.00105	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SHH—skin cancer	3.38e-06	0.00102	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RASA1—skin cancer	3.36e-06	0.00101	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PLIN2—skin cancer	3.36e-06	0.00101	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SMO—skin cancer	3.2e-06	0.000965	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTCH1—skin cancer	3.2e-06	0.000965	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—FOXO4—skin cancer	3.14e-06	0.000947	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CSPG4—skin cancer	3.12e-06	0.000941	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTGER4—skin cancer	3.12e-06	0.00094	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—HRAS—skin cancer	3.03e-06	0.000913	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	3e-06	0.000904	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PLIN2—skin cancer	3e-06	0.000903	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ENO2—skin cancer	2.96e-06	0.000893	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ENO2—skin cancer	2.94e-06	0.000885	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PLIN2—skin cancer	2.93e-06	0.000881	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—IL6—skin cancer	2.9e-06	0.000874	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SHH—skin cancer	2.86e-06	0.000861	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RASA1—skin cancer	2.84e-06	0.000855	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PLIN2—skin cancer	2.76e-06	0.00083	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—FOXO4—skin cancer	2.76e-06	0.00083	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PLIN2—skin cancer	2.73e-06	0.000823	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.73e-06	0.000823	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTCH1—skin cancer	2.71e-06	0.000816	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SMO—skin cancer	2.71e-06	0.000816	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CSPG4—skin cancer	2.71e-06	0.000815	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ENO2—skin cancer	2.69e-06	0.000811	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTGER4—skin cancer	2.64e-06	0.000794	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—ERCC2—skin cancer	2.57e-06	0.000773	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—NRAS—skin cancer	2.45e-06	0.000737	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CSPG4—skin cancer	2.42e-06	0.000728	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CSPG4—skin cancer	2.36e-06	0.00071	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PLIN2—skin cancer	2.34e-06	0.000704	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—FOXO4—skin cancer	2.33e-06	0.000702	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CSPG4—skin cancer	2.22e-06	0.000669	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CSPG4—skin cancer	2.2e-06	0.000664	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ENO2—skin cancer	2.12e-06	0.00064	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—KRAS—skin cancer	2.11e-06	0.000635	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TERT—skin cancer	2.1e-06	0.000632	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ERCC2—skin cancer	2.03e-06	0.000611	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.01e-06	0.000606	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CSPG4—skin cancer	1.88e-06	0.000567	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TP53—skin cancer	1.87e-06	0.000564	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TERT—skin cancer	1.84e-06	0.000554	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ENO2—skin cancer	1.84e-06	0.000554	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PLIN2—skin cancer	1.8e-06	0.000543	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—HRAS—skin cancer	1.79e-06	0.000539	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.79e-06	0.000538	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—NRAS—skin cancer	1.77e-06	0.000533	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ERCC2—skin cancer	1.72e-06	0.000519	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IL6—skin cancer	1.71e-06	0.000516	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ERCC2—skin cancer	1.71e-06	0.000514	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—BRAF—skin cancer	1.66e-06	0.000501	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ENO2—skin cancer	1.64e-06	0.000495	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ENO2—skin cancer	1.6e-06	0.000483	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ERCC2—skin cancer	1.56e-06	0.000471	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TERT—skin cancer	1.56e-06	0.000469	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—NRAS—skin cancer	1.55e-06	0.000467	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTGS2—skin cancer	1.54e-06	0.000464	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—KRAS—skin cancer	1.52e-06	0.000459	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ENO2—skin cancer	1.51e-06	0.000455	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ENO2—skin cancer	1.5e-06	0.000451	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—BRAF—skin cancer	1.46e-06	0.000439	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CSPG4—skin cancer	1.45e-06	0.000438	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.44e-06	0.000433	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—KRAS—skin cancer	1.33e-06	0.000402	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—NRAS—skin cancer	1.31e-06	0.000395	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—HRAS—skin cancer	1.29e-06	0.00039	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.28e-06	0.000387	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ENO2—skin cancer	1.28e-06	0.000385	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL6—skin cancer	1.24e-06	0.000373	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ERCC2—skin cancer	1.23e-06	0.000372	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—BRAF—skin cancer	1.23e-06	0.000371	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—skin cancer	1.22e-06	0.000367	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.17e-06	0.000353	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HRAS—skin cancer	1.13e-06	0.000342	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—KRAS—skin cancer	1.13e-06	0.00034	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL6—skin cancer	1.09e-06	0.000327	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ERCC2—skin cancer	1.07e-06	0.000322	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NRAS—skin cancer	1.04e-06	0.000315	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—skin cancer	1.03e-06	0.000311	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—skin cancer	1.02e-06	0.000308	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1e-06	0.000301	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ENO2—skin cancer	9.88e-07	0.000297	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HRAS—skin cancer	9.59e-07	0.000289	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ERCC2—skin cancer	9.54e-07	0.000287	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—skin cancer	9.38e-07	0.000283	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ERCC2—skin cancer	9.31e-07	0.00028	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL6—skin cancer	9.18e-07	0.000276	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NRAS—skin cancer	9.16e-07	0.000276	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KRAS—skin cancer	8.99e-07	0.000271	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ERCC2—skin cancer	8.77e-07	0.000264	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ERCC2—skin cancer	8.7e-07	0.000262	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—skin cancer	7.99e-07	0.000241	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KRAS—skin cancer	7.88e-07	0.000238	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NRAS—skin cancer	7.74e-07	0.000233	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HRAS—skin cancer	7.64e-07	0.00023	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ERCC2—skin cancer	7.43e-07	0.000224	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—skin cancer	7.4e-07	0.000223	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL6—skin cancer	7.31e-07	0.00022	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—skin cancer	7.01e-07	0.000211	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HRAS—skin cancer	6.7e-07	0.000202	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KRAS—skin cancer	6.66e-07	0.000201	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6—skin cancer	6.41e-07	0.000193	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—skin cancer	6.41e-07	0.000193	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—skin cancer	5.92e-07	0.000178	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ERCC2—skin cancer	5.74e-07	0.000173	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—skin cancer	5.72e-07	0.000172	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HRAS—skin cancer	5.66e-07	0.000171	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—skin cancer	5.58e-07	0.000168	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6—skin cancer	5.42e-07	0.000163	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—skin cancer	5.26e-07	0.000158	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—skin cancer	5.22e-07	0.000157	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—skin cancer	4.46e-07	0.000134	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—skin cancer	3.44e-07	0.000104	CbGpPWpGaD
